レジェネロン製薬は,主要投資家からの保有額が増え,強力な利益を報告し,市場資本額を69.68億ドルに押し上げました. Regeneron Pharmaceuticals saw increased holdings from major investors and reported strong earnings, boosting its $69.68B market cap.

DnB アセットマネジメントとQuantbot Technologiesはバイオ医薬品会社Regeneron Pharmaceuticals (NASDAQ: REGN) の持有権を拡大し,Pictet Asset Managementは持有権を削減した. DnB Asset Management and Quantbot Technologies have increased their holdings in biopharmaceutical company Regeneron Pharmaceuticals (NASDAQ: REGN), while Pictet Asset Management reduced its stake. レジェネロン社は,株当たり12.07ドルという 4 季度の強い利益を報告し,予想を上回り,収益は37億9000万ドルでした. Regeneron reported strong fourth-quarter earnings of $12.07 per share, beating estimates, with revenue at $3.79 billion. 会社の市場キャップは69. 6億6000億円で,アナリストが"モデレータ・バイヤー"と評価している. The company's market cap stands at $69.68 billion, and it is rated as a "Moderate Buy" by analysts.